Ribavirin microbiology

Ribavirin
REBETOL^® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Microbiology

Antiviral Activity in Cell Culture

The antiviral activity of ribavirin in the HCV-replicon is not well understood and has not been defined because of the cellular toxicity of ribavirin. Direct antiviral activity has been observed in tissue culture of other RNA viruses. The anti-HCV activity of interferon was demonstrated in cell containing self-replicating HCV-RNS (HCV replicon cells) or HCV infection.

Resistance

HCV genotypes show wide variability in their response to pegylated recombinant human interferon/ribavirin therapy. Genetic changes associated with the variable response have not been identified.

Cross-resistance

There is no reported cross-resistance between pegylated/non-pegylated interferons and ribavirin.^[1]

References

↑ “REBETOL (RIBAVIRIN) CAPSULE REBETOL (RIBAVIRIN) LIQUID [MERCK SHARP & DOHME CORP.]”. Retrieved 6 January 2014.

Adapted from the FDA Package Insert.

[dailymed.nlm.nih.gov-1] “REBETOL (RIBAVIRIN) CAPSULE REBETOL (RIBAVIRIN) LIQUID [MERCK SHARP & DOHME CORP.]”. Retrieved 6 January 2014.

[1]